NCT03344094View on ClinicalTrials.gov

Mechanism of Action of Ocrelizumab in Multiple Sclerosis

CompletedOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

February 23, 2018

Primary Completion Date

April 10, 2019

Study Completion Date

April 10, 2019

Conditions
Multiple SclerosisImmune System Diseases
Interventions
DRUG

ocrelizumab

FDA-approved MS drugs

Trial Locations (1)

60637

University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER

NCT03344094 - Mechanism of Action of Ocrelizumab in Multiple Sclerosis | Biotech Hunter | Biotech Hunter